From the Volume XXVI No. 3 – February 25, 2019 issue
BIGGER PATHOLOGY GROUPS AND METROWIDE OR STATEWIDE COVERAGE will be major characteristics in the anatomic pathology profession as healthcare continues to transform in new ways. That is why the reasons for the substantial growth in case volume and revenue at North Shore Pathologists (NSP) in Milwaukee should be studied by pathology groups everywhere.
It was a practice
From the Volume XXVI No. 2 – February 4, 2019 issue
By any measure, it is tougher today for clinical laboratories and anatomic pathology groups to generate the revenue needed to deliver state-of-the-art diagnostic testing services while remaining financially viable. Four recent trends prove the point.
First, every year, the Medicare program and private health insurers are cutting the prices they pay for medical laboratory tests.
Second, most
From the Volume XXVI No. 1 – January 14, 2019 issue
It may be timely to ask a provocative question that touches everyone in the profession of laboratory medicine. Is there a future for community laboratories and hospital lab outreach programs in the United States, given the different forces acting upon the clinical laboratory industry today?
In this issue, our editorial team describes the multiple disruptive consequences
From the Volume XXV No. 18 – December 24, 2018 issue
Each time a new year approaches, it is natural to look ahead and think about what the next 12 months will bring. My bet is that certain sectors of the clinical laboratory industry are soon to experience substantial disruption.
This disruption will come in two forms. First, federal regulators will be tougher on labs that violate
From the Volume XXV No. 17 – December 3, 2018 issue
Traditionally, the new year is a time of optimism. People make resolutions such as exercising more and losing weight. Companies get to start the year with a fresh budget and the new opportunity to achieve their goals.
Unfortunately, events of the last 90 days of this year are not auspicious for clinical laboratories and anatomic pathology
From the Volume XXV No. 16 – November 13, 2018 issue
How many consecutive 10% and 15% cuts to the prices Medicare pays for clinical laboratory tests can smaller community labs absorb before they are forced to shut their doors and go out of business? This nation is about to find out. As this happens, Medicare beneficiaries (and their physicians) in small towns and rural areas
From the Volume XXV No. 15 – October 22, 2018 issue
There is an important new development in the lawsuit in federal court that challenges how the Department of Health and Human Services (HHS) is implementing the Protecting Access to Medicare Act of 2014 (PAMA). An appeal was filed by attorneys representing the American Clinical Laboratory Association (ACLA).
On Friday, Oct. 19, the ACLA’s lead attorney on the case, Mark D.
From the Volume XXV No. 14 – October 1, 2018 issue
Every pathologist and clinical lab administrator should pay attention to two federal court decisions made recently in two different legal cases. One decision is bad news for the entire clinical lab industry. The other is bad news for lab companies that push compliance with federal anti-kickback laws.
The most important court decision came in the American
From the Volume XXV No. 13 – September 10, 2018 issue
STEP BY STEP, HEALTHCARE IN THE UNITED STATES is moving toward a system in which clinical care is fully integrated and providers are reimbursed for the value they provide. This trend presents clinical laboratories and anatomic pathology groups with a challenge and an opportunity.
The challenge comes because being a value-added contributor requires labs to adopt
From the Volume XXV No. 12 – August 20, 2018 issue
FOR MORE THAN TWO DECADES, leaders and forward-thinkers in the pathology profession bemoaned the fact that lab tests and anatomic pathology services were priced as commodities. From the podiums of various lab and healthcare conferences, they urged their peers to identify, document, and educate health insurers and others about the true value of lab tests.
All
